193 related articles for article (PubMed ID: 37605274)
21. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
Yong CM; Yehgambaram PAP; Lee SWH
PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
[TBL] [Abstract][Full Text] [Related]
22. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
Boidot R; Blum MGB; Wissler MP; Gottin C; Ruzicka J; Chevrier S; Delhomme TM; Audoux J; Jeanniard A; Just PA; Harter P; Pignata S; González-Martin A; Marth C; Mäenpää J; Colombo N; Vergote I; Fujiwara K; Duforet-Frebourg N; Bertrand D; Philippe N; Ray-Coquard I; Pujade-Lauraine E;
Eur J Cancer; 2024 May; 202():113978. PubMed ID: 38471290
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
Sabatier R; Rousseau F; Joly F; Cropet C; Montégut C; Frindte J; Cinieri S; Guerra Alía EM; Polterauer S; Yoshida H; Vergote I; Colombo N; Hietanen S; Largillier R; Canzler U; Gratet A; Marmé F; Favier L; Pujade-Lauraine E; Ray-Coquard I
Eur J Cancer; 2023 Mar; 181():42-52. PubMed ID: 36634389
[TBL] [Abstract][Full Text] [Related]
25. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
[TBL] [Abstract][Full Text] [Related]
26. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
[TBL] [Abstract][Full Text] [Related]
27. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
29. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
[TBL] [Abstract][Full Text] [Related]
32. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R; Muller E; Legros A; Goardon N; Chentli I; Atkinson A; Tranchant A; Castera L; Krieger S; Ricou A; Boulouard F; Joly F; Boucly R; Dumont A; Basset N; Coulet F; Chevalier LM; Rouleau E; Leitner K; González-Martin A; Gargiulo P; Lück HJ; Genestie C; ; Ray-Coquard I; Pujade-Lauraine E; Vaur D
Clin Cancer Res; 2023 Nov; 29(21):4419-4429. PubMed ID: 37756555
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
Leung JH; Lang HC; Wang SY; Lo HF; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):489-496. PubMed ID: 34241562
[TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Teppala S; Scuffham PA; Tuffaha H
Int J Technol Assess Health Care; 2024 Mar; 40(1):e14. PubMed ID: 38439629
[TBL] [Abstract][Full Text] [Related]
37. Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Barrington DA; Tubbs C; Smith HJ; Straughn JM; Senter L; Cohn DE
Int J Gynecol Cancer; 2020 Oct; 30(10):1569-1575. PubMed ID: 32753559
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Wu B; Shi L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
40. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
